Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.67 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.67 |
| ▸ | LGALS4 | P56470 | 3/20 | 0.67 |
| ▸ | IGF2R | P11717 | 2/20 | 0.51 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.47 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.47 |
| ▸ | GJB2 | P29033 | 1/20 | 0.47 |
| ▸ | TYR | P14679 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4264347 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RCD209 | |
| SCHEMBL17263250 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RCD209 | |
| SCHEMBL17547757 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RCD209 | |
| SCHEMBL15883873 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RCD209 | |
| SCHEMBL17547755 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RCD209 | |
| SCHEMBL6815726 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RCD209 | |
| SCHEMBL10292030 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RCD209 | |
| SCHEMBL10261434 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RCD209 | |
| SCHEMBL18386243 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RCD209 | |
| SCHEMBL20438916 | 1.00 | LGALS3 (0.67) | LGALS3LGALS8LGALS4IGF2RCD209 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-20020142046-A1 | Protein particles for therapeutic and diagnostic use | YEN, RICHARD C.K. | 2002-10-03 | — | — | US | disclosed |
| US-6391343-B1 | PARTICLE COMPRISING FIBRINOGEN BOUND ON SURFACE OF ALBUMIN MATRIX, CAPABLE OF CO-AGGREGATION WITH PLATELETS, AND OF AGGREGATION IN SOLUTION CONTAINING SOLUBLE FIBRINOGEN AT CONCENTRATION NOT CAPABLE OF CLOT FORMATION BY ITSELF | HEMOSPHERE, INC. | 2002-05-21 | — | — | US | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| US-5945033-A | ALBUMIN, HEMOGLOBIN MIXTURE; STABILITY | HEMOSPHERE, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5725804-A | ALBUMIN PARTICLES STABLE TO RESOLUBILIZATION, POLYOXYETHYLENE GLYCOL, ALCOHOL | HEMOSPHERE, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| US-5616311-A | AQUEOUS ALBUMIN SUSPENSION STABILIZED BY HEMOGLOBIN PARTICLES | HEMOSPHERE, INC. (US) | 1997-04-01 | — | — | US | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
| WO-1992003122-A1 | PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS | CEVC GREGOR (DE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | LGALS3 347/4885LGALS8 437/4885LGALS4 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.